<DOC>
	<DOCNO>NCT02970292</DOCNO>
	<brief_summary>To evaluate efficacy safety adjunctive pimavanserin compare adjunctive placebo treatment schizophrenia</brief_summary>
	<brief_title>Efficacy Safety Adjunctive Pimavanserin Treatment Schizophrenia ( ENHANCE-1 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Pimavanserin</mesh_term>
	<criteria>1 . Adults patient , age 18 year 2 . A clinical diagnosis schizophrenia minimum duration 1 year 3 . Has equal less 10 year treatment antipsychotic 4 . The main background antipsychotic subject treat must one antipsychotic list : Aripiprazole Risperidone Olanzapine Lurasidone Cariprazine Brexpiprazole Asenapine Risperidone longacting injection Aripiprazole longacting injectables : Abilify Maintena® Aristada® 5 . Has partial inadequate response antipsychotic treatment 6 . Has history response antipsychotic treatment clozapine 1 . Patient psychiatric disorder schizophrenia 2 . Patient history resistance antipsychotic treatment 3 . Patient current evidence serious and/or unstable neurologic , cardiovascular , respiratory , gastrointestinal , renal , hepatic , hematologic , medical disorder , include cancer malignancy , would affect patient 's ability participate program 4 . Patient myocardial infarction last six month 5 . Patient take medication drug prolongs QT interval history symptom long QT syndrome Patients evaluate screening ensure criterion study participation met . Patients may exclude study base assessment ( specifically determine baseline health psychiatric condition meet prespecified entry criterion ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>